A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
<h2>ABSTRACT</h2><h3>Background</h3><p>Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize chemotherapy-induced nausea and vomiting (CINV) control in patients receiving highly emetogenic chemothera...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Annals of oncology
Year: 2017, Jahrgang: 29, Heft: 2, Pages: 452-458 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdx698 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdx698 Verlag, lizenzpflichtig, Volltext: https://www.annalsofoncology.org/article/S0923-7534(19)35044-6/abstract 
|
| Verfasserangaben: | L. Zhang, S. Lu, J. Feng, A. Dechaphunkul, J. Chang, D. Wang, S. Chessari, C. Lanzarotti, K. Jordan & M. Aapro |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693614863 | ||
| 003 | DE-627 | ||
| 005 | 20230427031647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200331r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdx698 |2 doi | |
| 035 | |a (DE-627)1693614863 | ||
| 035 | |a (DE-599)KXP1693614863 | ||
| 035 | |a (OCoLC)1341311758 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zhang, Li |e VerfasserIn |0 (DE-588)1207343080 |0 (DE-627)1693616173 |4 aut | |
| 245 | 1 | 2 | |a A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) |c L. Zhang, S. Lu, J. Feng, A. Dechaphunkul, J. Chang, D. Wang, S. Chessari, C. Lanzarotti, K. Jordan & M. Aapro |
| 246 | 3 | 0 | |a third |
| 264 | 1 | |c 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online 28 October 2017 | ||
| 500 | |a Gesehen am 31.03.2020 | ||
| 520 | |a <h2>ABSTRACT</h2><h3>Background</h3><p>Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize chemotherapy-induced nausea and vomiting (CINV) control in patients receiving highly emetogenic chemotherapy (HEC). NEPA, a fixed combination of a highly selective NK<sub>1</sub> receptor antagonist, netupitant (300 mg), and the pharmacologically distinct 5-HT<sub>3</sub>RA, palonosetron (PALO 0.50 mg), has shown superior CINV prevention compared with PALO in cisplatin and anthracycline/cyclophosphamide-based settings. This study is the first head-to-head comparison of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.</p><h3>Patients and methods</h3><p>This randomized, double-blind phase III study conducted in Asia was designed with the primary objective to demonstrate non-inferiority of a single oral dose of NEPA compared with a 3-day oral APR/GRAN regimen in chemotherapy-naïve patients receiving cisplatin-based HEC. All patients also received oral dexamethasone (DEX) on days 1-4. The primary efficacy endpoint was complete response (CR: no emesis/no rescue medication) during the overall (0-120 h) phase. Non-inferiority was defined as a lower 95% CI greater than the non-inferiority margin set at −10%. Secondary efficacy endpoints included no emesis, no rescue medication, and no significant nausea (NSN).</p><h3>Results</h3><p>Treatment groups were comparable for the 828 patients analyzed: predominantly male (71%); mean age 54.5 years; ECOG 0-1 (98%); lung cancer (58%). NEPA demonstrated non-inferiority to APR/GRAN for overall CR [NEPA 73.8% versus APR/GRAN 72.4%, 95% CI (−4.5%, 7.5%)]. No emesis [NEPA 75.0% versus APR/GRAN 74.0%, 95% CI (−4.8%, 6.9%)] and NSN rates [NEPA 75.7% versus APR/GRAN 70.4%, 95% CI (−0.6%, 11.4%)] were similar between groups, but significantly more NEPA patients did not take rescue medication [NEPA 96.6% versus APR/GRAN 93.5%, 95% CI (0.2%, 6.1%)]. NEPA was well tolerated with a similar safety profile to APR/GRAN.</p><h3>Conclusions</h3><p>In this first study comparing NK<sub>1</sub>RA regimens and DEX, NEPA administered only on day 1 was non-inferior to a 3-day oral APR/GRAN regimen in preventing CINV associated with HEC.</p> | ||
| 534 | |c 2017 | ||
| 700 | 1 | |a Jordan, Karin |d 1974- |e VerfasserIn |0 (DE-588)123243327 |0 (DE-627)706224078 |0 (DE-576)293619174 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 29(2018), 2, Seite 452-458 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) |
| 773 | 1 | 8 | |g volume:29 |g year:2018 |g number:2 |g pages:452-458 |g extent:7 |a A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) |
| 856 | 4 | 0 | |u https://doi.org/10.1093/annonc/mdx698 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.annalsofoncology.org/article/S0923-7534(19)35044-6/abstract |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200331 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 123243327 |a Jordan, Karin |m 123243327:Jordan, Karin |d 910000 |d 910100 |e 910000PJ123243327 |e 910100PJ123243327 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 999 | |a KXP-PPN1693614863 |e 3616437369 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1693614863","note":["Published online 28 October 2017","Gesehen am 31.03.2020"],"name":{"displayForm":["L. Zhang, S. Lu, J. Feng, A. Dechaphunkul, J. Chang, D. Wang, S. Chessari, C. Lanzarotti, K. Jordan & M. Aapro"]},"relHost":[{"disp":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)Annals of oncology","note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"pubHistory":["1.1990 -"],"recId":"320428796","origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press"}],"id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"29","text":"29(2018), 2, Seite 452-458","pages":"452-458","extent":"7","year":"2018","issue":"2"},"title":[{"title_sort":"Annals of oncology","title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"7 S."}],"person":[{"role":"aut","given":"Li","display":"Zhang, Li","family":"Zhang"},{"given":"Karin","display":"Jordan, Karin","family":"Jordan","role":"aut"}],"title":[{"title_sort":"randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)"}],"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"id":{"eki":["1693614863"],"doi":["10.1093/annonc/mdx698"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a ZHANGLIJORRANDOMIZED2018 | ||